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Abstract
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Purpose of review: Pulmonary hypertension is characterized by an elevation of pulmonary
artery pressures and prolonged exposure of the right ventricle to high afterload that collectively
contribute to morbidity and mortality in both the term and preterm infants. This review
summarizes the pathogenesis, etiologies, and hemodynamics profiles of the conditions that result
in pulmonary hypertension in neonates. We explore the application of echocardiographic
techniques for the assessment of right ventricular performance and pulmonary hemodynamics that
enhance and guide the diagnosis and management strategies in neonates.
Recent Findings: Clinical assessments based on the determinants of mean pulmonary artery
pressures (pulmonary vascular resistance, pulmonary blood flow, and pulmonary capillary wedge
pressure) provide a physiologic approach for determining the acute and chronic etiologies of
pulmonary hypertension in neonates. In addition, advances in neonatal echocardiography now
afford the capability to obtain quantitative information that often precedes the qualitative
information acquired by conventional methods and also provide sensitive markers of right
ventricle performance for prognostic information based on the determinants of mean pulmonary
artery pressures.
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Summary: Neonatal pulmonary hypertension represents a physiologic spectrum that accounts for
the variance in clinical presentation and response to therapies. Physiology based approaches to
etiology identification, coupled with the emerging echocardiographic methods for the assessment
of pulmonary hypertension in neonates will likely help to identify cardiovascular compromise
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earlier, guide therapeutic intervention, monitor therapeutic effectiveness, and improve overall
outcome.
Keywords
Pulmonary hypertension; Right Ventricle; Heart function; Neonatology; Echocardiography

INTRODUCTION
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Pulmonary hypertension (PHT) is characterized by a state of sustained elevation of
pulmonary artery pressures (PAP) and prolonged exposure of the right ventricle (RV) to high
afterload that collectively contribute to morbidity and mortality in both the term and preterm
infants. The diagnosis and management of the hemodynamic status of neonates with PHT is
challenging, owing to the multitude of etiologies and the unique characteristics of the
pulmonary circulatory system. Although mean PAP (mPAP) is directly related to pulmonary
blood flow (PBF) and pulmonary capillary wedge pressure (PWCP), the pathophysiological
hallmark of neonatal PHT is increased pulmonary vascular resistance (PVR)(1). In acute
PHT (aPHT), failure of reduction in PVR during the postnatal transitional period results in
impaired oxygenation, RV failure, and pulmonary-to-systemic shunting. Chronic PHT
(cPHT) may also result from exposure to high PBF or PCWP but traditionally occurs
secondary to a rise in PVR beyond the first month of age (often with initial successful
postnatal transition) that is seen most frequently with chronic neonatal lung diseases. In this
review, we discuss the embryologic origins of RV and pulmonary circulatory development
and the pathogenesis, various etiologies and hemodynamic profiles of PHT in term and
preterm neonates. We examine the application of echocardiographic techniques that enhance
and guide the diagnosis and management strategies in neonates.
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PULMONARY CIRCULATION AND RIGHT VENTRICLE DEVELOPMENT

Author Manuscript

Cardiac morphogenesis initially precedes airway development, but distinctive elements of
the pulmonary system arise from primitive heart tube during the embryonic stage(2). The
genetic investigation of cardiac morphogenesis has shown that the cells of the anterior
second heart field develop into the RV during the looping process and form the main
pulmonary arterial trunk(3). The pulmonary arterial precursors then form a multilayered
vascular network linking the arterial and venous poles of the heart with a continuous
circulation between the RV and lungs. The pulmonary circulation subsequently arises shortly
thereafter through temporal and spatially controlled signaling pathways linked to both the
cardiac and airway development(3). The RV and pulmonary circulation are separated from
the left ventricle (LV) and systemic circulation by atrial and ventricular septation, although
they remain a parallel circulation during fetal life through a patent foramen ovale and ductus
arteriosus. At birth, inflation of the lungs, increased oxygen tension and appropriate
reduction in PVR allow increased pulmonary blood flow to the left side of the heart resulting
in closure of the remaining fetal shunts.
The RV develops as a complex tripartite structure made up of an inflow area, trabeculated
apex, and smooth outlet infundibulum leading into the pulmonary arterial circulation. The
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coarse trabeculations and thin-walled structure allow the RV to acutely dilate to
accommodate increases in volume and afterload. The RV is the dominant chamber in the
fetal period, supplying 45–60% of the total cardiac output depending of the stage of
gestation(4). The pulmonary arterial circulation consists of thin, elastic vessels that
accompany the arborization of the bronchial airway but remain constricted by vasoactive
mediators. Only 15–25% of the total cardiac output circulates through the pulmonary
vasculature with the remaining RV output redirected through the ductus arteriosus (DA) into
the systemic circulation.

ETIO-PATHOGENESIS OF PULMONARY HYPERTENSION

Author Manuscript
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Mean PAP (mPAP) is directly proportional to PBF, PVR, and PCWP and can be summarized
as the following equation: mPAP = (PBF × PVR) + PCWP(1). An increase in any of the
three determinants of mPAP can lead to PHT (Figure 1). Flow related PHT has acutely been
reported in the context of arterial venous malformations(5, 6) and chronically with left-toright intra- and extra- cardiac shunts, e.g. atrial septal defect (ASD), ventricular septal
defects (VSD) and patent DA (PDA)(1, 7). The hemodynamically significant left-to-right
shunts can result in chronic pulmonary overcirculation adding an extra stressor to the
immature pulmonary vasculature in the preterm infant and predisposing it to vascular
remodeling and potential development of PHT. Increased PCWP may also lead to pulmonary
venous congestion and PHT in neonates. Etiologies include left atrial and ventricular
dysfunction seen in prematurity(8) and infants with hypoxic ischemic encephalopathy(HIE)
(9). Pulmonary vein stenosis may also result in PHT in premature infants and has been
observed with growing frequency in infants with chronic lung disease (CLD)(10). Although
the exact mechanistic link is unknown, possible pathways include abnormal angiogenesis
related to CLD, chronic pulmonary over-circulation from concomitant left-to-right shunting
lesions, and increased PCWP(10).

Author Manuscript

Though the above mechanisms of elevated PBF and PCWP lead to raised pulmonary
pressures, in practice, increased PVR resulting from a combination of intrinsic, secondary,
and acquired abnormalities in the pulmonary vasculature is widely recognized as the
pathophysiologic hallmark of neonatal PHT. In the absence of intracardiac shunts, PVR is
defined as the transpulmonary pressure gradient divided by PBF, and refers to the resistance
that the RV must overcome to provide antegrade flow to the pulmonary circulation. The
major determinants of PVR are the pulmonary arterial count, capillary vascular bed
structure, and vasomotor tone. There are five cellular pathways involved in regulation of
pulmonary vascular tone: (1) nitric oxide (NO)-soluble guanylate cyclase-cyclic guanyl
monophosphate (cGMP); (2) prostaglandin-prostacyclin-cyclic adenosine monophosphate
(cAMP); (3) RhoKinase; (4) endothelin; and (5) reactive oxygen species (ROS)(7). Isolated
abnormal vasoreactivity from interruption of these cellular pathways in combination with
structurally abnormal pulmonary vasculature are the major causes of high PVR related PHT
in neonates.
In the fetal circulation, the highly vascular, low resistance placenta serves as the organ for
gas exchange, receiving oxygenated blood from the maternal circulation and contributing to
a lowered fetal systemic vascular resistance (SVR)(11, 12). The lungs only receive a small
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amount of blood flow due to the vasoconstricted state (high PVR) of the fetal pulmonary
vasculature(12). In utero pulmonary vasoconstriction is maintained by several mechanisms,
including fetal lung fluid, low oxygen tension, release of the endogenous vasoconstrictors
(e.g. endothelin-1, thromboxane, and platelet activating factor), ROS, and increased Rho ARho Kinase(13). The immediate postnatal period is regulated by the complex interplay
between local vasoconstrictor and vasodilator mediators and transitional circulatory events
to ensure a smooth move from fetal to extrauterine life. Clamping of the umbilical cord
removes the low-resistance placental flow with a subsequent rise in the systemic afterload
(SVR), and the first breath of oxygenated air results in lung expansion and relief of alveolar
hypoxia that dramatically decreases PVR leaving the postnatal pulmonary circulation as a
low pressure, low resistance, high flow system. Pulmonary vasodilation is further regulated
by postnatal mechanical distention, decrease in carbon dioxide tension, increase in oxygen
tension, surge of vasodilator prostaglandins, and release of NO(14, 15). Conditions that
interfere with the normal postnatal decline in the PVR/SVR ratio coupled with mediators
that promote vasoconstriction and negate vasodilation cause the transitional circulation to
persist and result in aPHT.
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There are three types of etiological abnormalities of the pulmonary vasculature that underlie
PHT and lead to elevated PVR. (1) Primary or idiopathic PHT is characterized by
remodeling of the pulmonary vessels (structure and number) with vascular wall thickening
and smooth muscle hyperplasia. The pulmonary vasculature is maldeveloped with normal
lung parenchyma. As the smooth muscle extends to the level of the intra-acinar arteries, a
process that normally occurs much later in the postnatal period, the pulmonary vasculature
will not vasodilate appropriately in response to birth-related stimuli. In addition, there is
disruption of the cellular signaling pathways and these neonates present with profound
hypoxemia and clear, hyperlucent lung fields. (2) In secondary PHT, the pulmonary
vasculature is structurally normal but with abnormal vasoreactivity affecting the transitional
reduction of PVR; this can often be reversed. The pulmonary vasculature maladapts at birth
due to parenchymal lung disease processes (e.g. respiratory distress syndrome (RDS),
meconium aspiration syndrome, pneumonia, and air leak) that affect oxygenation,
ventilation, and lung recruitment. Extra-parenchymal disorders such as perinatal asphyxia
with acidosis and sepsis can also contribute to this phenomenon(1). The third common cause
of PVR related PHT is pulmonary vascular hypoplasia that is underdeveloped and often
refractory or irreversible, depending on the nature of underlying involvement(7). Primary
causes include alveolar capillary dysplasia with misalignment of pulmonary veins,
pulmonary interstitial lymphangiectasia, primary surfactant metabolism disorders, or
congenital diaphragmatic hernia (CDH). Secondary causes are associated with restrictive
lung growth and absence of/decreased fetal breathing.
While this traditional etiologic categorization of pulmonary vasculature is helpful, a more
recent approach complements the current classification by differentiating neonatal PHT by
its clinical phenotype, aPHT or cPHT(1). aPHT presents in the immediate postnatal period
secondary to abnormal transition of the pulmonary circulation from a high-resistance
intrauterine to a low-resistance extrauterine circuit. This is often referred to as persistent
pulmonary hypertension of the newborn (PPHN). However, the term “PPHN” can
misrepresent the normal physiologic process in the transitional period, as elevated mPAP is
Curr Treat Options Cardiovasc Med. Author manuscript; available in PMC 2020 February 15.
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ubiquitous(16). Giesinger et al.(16) suggest the term “aPHT” may be more appropriate
because it provides an accurate representation of the pathophysiologic disturbances with
elevated mPAP, oxygenation failure, and potential RV dysfunction. In contrast, “Chronic
PHT” in neonates is secondary to a rise in PVR outside of the transition period and can be
observed with chronic neonatal lung diseases associated with prematurity, chronic vascular
remodeling due to pulmonary overcirculation from left-to-right shunting, or genetic
predisposition(1).

Author Manuscript

aPHT is traditionally considered a disease of term and late preterm infants, but recently,
prematurity has also been identified as an independent risk factor(17, 18). aPHT is
recognized in 2–8% of preterm infants presenting with early RDS and up to 67% of preterm
infants with severe RDS(17–19). aPHT has also been recognized as a risk factor for
cPHT(20). The high incidence of parenchymal lung disease, sepsis exposure, physiological
immaturity of the NO pathway, and immature gas exchange mechanisms all play key roles in
the pathogenesis of aPHT in the preterm infant. Preterm infants with fetal growth restriction,
exposure to prolonged rupture of membranes with varying degrees of pulmonary hypoplasia,
and chorioamnionitis are also at higher risk of developing aPHT. The abnormal physiologic
consequences of PHT also contribute to delayed cardiopulmonary transition in premature
infants(16).

Author Manuscript

The entity of cPHT is characterized by a later presentation (>4–6 weeks chronological age)
with a gradual increase in PVR. Established cPHT is commonly associated with CLD(21).
Although the reported incidence of cPHT is 14–44%, with an association of 20–50%
mortality(22–25) in the infants with recognized CLD(20, 26), recent evidence indicates that
up to 20% of extremely low gestational age neonates without CLD will develop some degree
of pHTN evidence by echocardiography during the neonatal period(20, 27). Reduced
vascular branching, altered pattern of vascular distribution, disruption of vascular signaling
pathways, endothelial injury, and abnormal smooth muscle proliferation are some of the
underlying mechanisms of the late increase in PVR(28). Exacerbating factors include air
trapping induced abnormal stretch of small pulmonary arteries, atelectasis leading to
constraining pulmonary vessels, and acute episodes of hypoxia and hypercarbia, all of which
can induce pulmonary artery vasoconstriction and altered vessel morphology in premature
neonates(21).

CARDIOPULMONARY CONSEQUENCES: THE HEMODYNAMIC PROFILE OF
PHT
Author Manuscript

PHT leads to an array of complex hemodynamic consequences(1). The clinical presentation
depends on the onset and severity of the disease process. Awareness of the spectrum of
cardiopulmonary consequences of aPHT and cPHT facilitates appropriate monitoring and
guides anticipatory management(21). With aPHT there are different etiologies that affect the
cellular mechanisms, but the hemodynamic profile often remains the same. The elevated
mPAP that is present with sustained elevation of PVR related aPHT leads to failure of gas
exchange across the highly constricted pulmonary blood vessels; this manifests as cyanosis
and oxygenation failure from significant ventilation perfusion mismatch early in life. The
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underlying parenchymal lung disease may also dictate the extent of oxygenation difficulty.
Profound lability is another characteristic finding that indicates unstable pulmonary
vasoreactivity with worsening oxygenation that parallels increases in PVR with handling and
agitation(29).
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Neonatal PHT with persistent high PVR results in a direct increase in RV afterload(1). The
neonatal myocardium is exquisitely sensitive to afterload and often incapable of rapid
adaptation (this is even more pronounced in the preterm infant), perpetuating progressive RV
dilatation and dysfunction(29). The coexistence of high PVR and RV dysfunction can result
in critically low PBF. The increased RV systolic pressure with high PVR is transmitted to
the atrial level, leading to reversal of shunt across the patent foramen ovale and intra-cardiac
mixing of oxygenated and deoxygenated blood that clinically manifests as cyanosis. The
high mPAP also drives a bidirectional or possibly complete right-to-left shunt across the DA,
resulting in post-ductal mixing of deoxygenated blood and the classical presentation of
differential cyanosis. Although a right-to-left shunt across the DA may offload the
pulmonary circulation and mitigate some of the RV failure and systemic hypoperfusion, it
can reduce the myocardial oxygen demand and lead to further ventricular dysfunction. LV
filling may also be affected by reduced PBF, RV dilatation, and septal bowing. Varying
degree of LV dysfunction may manifest due to the phenomenon of inter-ventricular
dependence in the context of RV dysfunction. The diversion of PBF away from the lungs
may also cause acidosis and impede global myocardial performance, eventually leading to
further LV dysfunction with subsequent decline in LV output and clinical manifestations of
hypotension, shock, oliguria/anuria, and end organ compromise(1).

Author Manuscript

In contrast to the acute hypoxic respiratory failure and hemodynamic instability that
characterizes classic aPHT, the symptoms and clinical findings from chronically elevated
PAP are more subtle and insidious in cPHT(23, 30). The cPHT often manifests with oxygen
dependence, rather than oxygenation failure, and respiratory deterioration in the face of
expected improvement. Prolonged exposure to increased afterload in cPHT often leads to
RV dysfunction, both systolic and diastolic, manifesting through a constellation of marked
signs of progressive right heart failure including RV dilatation, dysfunction, hepatomegaly,
edema, excessive weight gain, and/or inability to establish oral feeding(30).

CLINICAL AND ECHOCARDIOGRAPHIC ASSESSMENT OF NEONATAL
PULMONARY HYPERTENSION

Author Manuscript

Hemodynamic appraisal of neonates with PHT begins with a comprehensive clinical history
to identify pertinent maternal, perinatal, and postnatal influences that can increase the risk of
cardiovascular compromise. Since objective measurement of cardiac output, systemic blood
flow, and end organ perfusion remain very challenging, assessment must combine various
clinical parameters (i.e. oxygen saturations, continuous blood pressure, heart rate, urine
output, capillary refill time, etc.), biochemical markers (lactate, base excess), and imaging
modalities (e.g. echocardiography) to provide the most complete and accurate picture of the
cause of hemodynamic instability, inform decision-making, and offer a possible therapeutic
approach(29). The use of echocardiography to assess for PHT and cardiovascular health in
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neonates has now become the standard of care(31, 32) with a growing recognition that it can
provide hemodynamic information that either complements what is clinically suspected or
delivers novel physiologic insight(29).
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Cardiac catheterization remains the gold standard for assessment of RV performance and
pulmonary hemodynamics, but it remains invasive and less than ideal in neonates when
searching for a modality to screen and monitor PHT in this population(33). The integration
of hemodynamic information obtained by transthoracic echocardiography relevant to the
etiology and clinical situation offers a vehicle for which to formulate a scientifically based
diagnostic impression, determine a pathophysiological choice for support, and evaluate the
response to therapeutic intervention(29). In order to provide a relevant blueprint for the
diagnosis of both aPHT and cPHT, we suggest classifying commonly used measurements
into three broad categories: (1) indirect assessment of elevated RV afterload, (2) estimation
of pulmonary hemodynamics, and (3) measures of right ventricular performance. (Left
ventricular performance is also important in the evaluation of neonatal PHT but beyond the
scope of this review).
Indirect assessment of elevated RV afterload
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There are several cardiopulmonary interactions that provide an indirect assessment of PHT
shown by evidence of elevated RV afterload. The size and shape of the interventricular
septum (IVS) can be a useful tool for qualitative assessment of elevated mPAP with the
degree of flattening in end-systole providing an estimate of RV systolic pressure (RVSP)
between 50–100% of the systemic pressures(34). The eccentricity index (EI) is a measure
that quantifies the ratio between LV anteroposterior and septolateral dimensions and
suggests elevated RV afterload when this ratio > 1.0(35). While LV diastolic EI is more a
marker of RV volume overload, systolic EI reflects RV pressure overload and is more useful
for PHT(36). Evidence of elevated PAP can be associated with RV dilation in aPHT and RV
hypertrophy in cPHT. Measuring systolic time intervals can provide insight to pulmonary
vascular impedance, compliance, and pressure(33). Pre-ejection period (PEP) is defined as
the onset of ventricular depolarization to beginning of pulmonary ejection and is directly
proportional to PAP(37). RV ejection time (RVET) is relative to stroke volume and has an
inverse relationship to pulmonary artery compliance. Pulmonary artery acceleration time
(PAAT) is the time interval from the onset to the peak of ejection and provides a strong
correlation to systolic PAP(33). Ratios of these respective intervals such as PEP/RVET and
PAAT/RVET have been shown to provide reliable estimates of invasive measures of
pulmonary hemodynamics and RV performance in both acute and chronic PHT(33, 38).

Author Manuscript

Estimation of Pulmonary Hemodynamics
Doppler interrogation of the tricuspid and pulmonary flow is useful in estimating ventricular
systolic pressures. In the setting of absent RV outflow tract obstruction, it can also predict
pulmonary artery systolic pressure (PASP). In neonates with tricuspid valve regurgitation
velocity (TRV), the modified Bernoulli equation can estimate RVSP by the following
equations: 4 × (TRV)2 + right atrial pressure(39). There are several limitations with this
equation, but the trend is often valuable for following neonates with aPHT and cPHT.
Pulmonary regurgitation velocity (PRV) has been shown to accurately measure both mPAP
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and end-diastolic pulmonary pressure by peak regurgitant velocity and end-diastolic
regurgitant velocity respectively(40). This is particularly useful to estimate the mean
transpulmonary gradient in the calculation of PVR and distinguishing left sided obstructive
disease. Using TRV to estimate RVSP, pulmonary artery diastolic pressure (PADP) can also
be estimated by the following equation: PADP = 0.49 × RVSP(41). Velocities across a VSD
and a PDA can also be used to estimate pulmonary pressures depending on the location,
length, and tortuosity.

Author Manuscript

PVR can be assessed with the TRV interrogation based on its relationship to velocity time
integral along the RV outflow tract (TRV:VTI)(42), dynamic compliance(43), and
pulmonary artery capacitance(44), all of which add value to understanding the degree of
pulmonary bed vasoreactivity. PVR can also be assessed by measuring RV systolic time
intervals (RVET, PAAT, PEP), as they have been shown to provide accurate estimates of
invasive measures of PVR and pulmonary artery compliance(33, 38).
Right Ventricular Performance

Author Manuscript

The complex cardiopulmonary interactions and myocardial remodeling seen in both aPHT
and cPHT result in varying degrees of systolic and diastolic ventricular dysfunction. RV
output (RVO) provides an estimate of PBF in the absence of RV outflow obstructions or
pulmonary-to-aortic shunts. Although there are limitations and considerations with proper
acquisition, serial measurements may provide insight into alterations in stroke volume and
PBF-related PHT. The geometric shape, fiber orientation, and coarse trabeculations make
estimating contractile function and defining ventricular borders difficult with conventional
2D echocardiography. Several novel and re-emerging measures have been validated to
overcome these concerns. Percent fractional area change (FAC) is a two-dimensional
measurement of surface area used to characterize RV global systolic function and has been
well studied in preterm and term infants(45, 46). Tricuspid annular plane systolic excursion
(TAPSE) measures the longitudinal excursion of the tricuspid valve from the base towards
the apex during systole (47). Although the RV has a complex three-dimensional myofiber
arrangement, the dominant longitudinal shortening measured by TAPSE provides the major
contribution to ejection fraction and stroke volume during systole(46). In addition, both
reduced values of FAC and TAPSE have been found to be predictive of increased mortality
in patients with PHT(48). The relationship of TAPSE to PAAT has recently been shown to
be inversely correlated with mPAP and PVR and directly correlated with pulmonary arterial
compliance and RV strain in a cohort of children(49). TAPSE:PAAT provides a reliable
estimate of RV-pulmonary vascular coupling(50).
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Other measures of RV performance, such as the systolic and diastolic time (SD/DD) and RV
myocardial performance index (MPI) are markers of global systolic and diastolic function
reflecting ventricular loading and contractility. An increase in SD/DD ratio is seen as a sign
of global RV dysfunction secondary to increased afterload; a level > 1.3 has been associated
with the need for extracorporeal membrane oxygenation (ECMO) or death(51). RV MPI
relates the sum of isovolumic contraction and relaxation time to the ejection time with
prolonged isovolumic intervals; higher MPI values are also suggestive of increased RV
afterload and ventricular dysfunction(51). Tissue Doppler imaging measures the peak

Curr Treat Options Cardiovasc Med. Author manuscript; available in PMC 2020 February 15.

Bhattacharya et al.

Page 9

Author Manuscript

systolic (s’), early diastolic (e’), late diastolic (a’), and peak isovolumetric contraction
velocities(52). Normative values exist in neonates and can provide longitudinal
measurements of RV diastolic performance in preterm infants(8). Speckle-tracking
echocardiography is used to assess global and free wall longitudinal strain and has been
shown to be a predictive measure of PHT in neonates and children(53).
Morphological measures of RV performance can also provide diagnostic clues for RV
hypertrophy and dilation. Structural assessments by echocardiography should include
measures of areas (end systolic and end diastolic)(45), cavity dimensions at the base, midcavity, and length of the RV from the apex to the middle of the base in the RV focused apical
4-chamber view. RV outflow dimensions can be obtained from either the parasternal long
axis or short axis view to assess the proximal and distal components of the RV outflow
tract(54).
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MANAGEMENT OF PULMONARY HYPERTENSION
Management of aPHT and cPHT both require attention to physiology with the aim of
promoting adequate PBF to improve the efficacy of oxygenation and reduce secondary
consequences of increased RV afterload(1). The initial management for PHT begins with
identification of risk factors, recognition of symptoms, and anticipation of potential illness.
The approach consists of three basic tenants: (1) supportive cardiorespiratory care, (2)
judicious use of pulmonary vasodilators, and/or (3) invasive extracorporeal membrane
oxygenation if needed.
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General cardiorespiratory measures may reverse or prevent further increase in pulmonary
vasoconstriction and include the following: (i) Correction of metabolic derangements,
including hypoglycemia, hypothermia, and acidosis; (ii) Maintenance of adequate
oxygenation with supplemental oxygen as the initial therapy in both aPHT and cPHT.
Although the target oxygen concentration ideal for optimizing outcomes for neonates is not
established, recent recommendations consider the goal to maintain oxygen saturations
between 92–95%(23, 55); (iii) Optimization of lung recruitment with mechanical ventilation
guided by the underlying mechanism of PHT and response to treatment. In cPHT ventilator
strategies should have a specific emphasis on avoiding air trapping and minimizing acidosis.
In the setting of hypoxemia caused by right-to-left shunting, rather than ventilationperfusion imbalance, minimizing mean airway pressure while maintaining adequate lung
recruitment and ensuring venous return may be most appropriate. Surfactant replacement
therapy can be considered for infants with aPHT and pulmonary diffusion impairment(56),
but early refractory hypoxemia despite effective ventilation strategies and targeted surfactant
administration, may relate to extreme lung immaturity in premature infants, with PH as a
contributing factor. (iv) Circulatory support with fluid resuscitation, inotropic agents, or
vasopressors to ensure adequate cardiac output and systemic perfusion may be necessary
with aPHT. While specific medications and their mechanisms of action are beyond the scope
of this review, steroid treatment to stabilize blood pressure in inotropic-resistant
environments may also be necessary. In addition to circulatory support, steroids may also
mitigate the chemical pneumonitis seen with meconium aspiration in aPHT with inhibition
of inflammation and decreasing cytokine-induced vasoconstriction. Laboratory evidence and
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clinical observations also suggest that modulating inflammation using glucocorticoids may
benefit neonates with cPHT(57); (v) Sedating agents should be considered in an effort to
avoid agitation and the catecholamine release that contributes to further increases in
afterload and hypoxemia from right-to-left shunting and asynchronous ventilation with
patient-triggered ventilator mode.
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Additional cardiorespiratory support measures may also be considered based on the
physiologic presentation. They include administration of packed red blood cell transfusion
for optimization of oxygen delivery(58) and antibiotic treatment with acute episodes of
neonatal PHT that can occur with sepsis physiology. Since pulmonary edema may also be a
major contributor to the symptoms of cPHT, diuretics may be considered when cardiac
preload is adequate and are especially important in the setting of shunt lesions(23, 30). In
flow related PHT, flow modulation strategies (e.g. medical/surgical closure of DA or
intracardiac shunt) may be required. In addition to appropriate ventilation strategies,
assessments for aspiration and structural airway disease should be performed prior to
considering PHT-targeted therapy.
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In severe cases, general supportive care may be insufficient to maintain adequate
oxygenation. PHT-targeted therapy should be considered for infants with sustained PHT
after optimal treatment of underlying respiratory and cardiac disease(23). Inhaled NO (iNO),
a potent and microselective pulmonary vasodilator, and ECMO are two therapeutic options
with scientifically proven benefits for infants with PHT who fail to respond to general
cardiopulmonary supportive care(59). In addition, several newer non-invasive therapeutic
agents have been developed, many of which are used routinely in clinical practice for
children and adults with PHT, but their efficacy and safety have not been tested in large
clinical trials in neonates(23). One way to approach the different therapeutic options for
PHT is to think of them with respects to the key mediator pathways listed above. Oxygen is
the starting point for all pathways(1). The NO-cGMP pathway has two recognized
therapeutic agents, iNO and sildenafil, for the treatment of PHT in neonates. iNO is
indicated in mechanically ventilated term and late preterm newborns if PaO2 <100 mmHg or
OI >25(55, 56). Although it has been studied and proven ineffective for the prevention of
CLD in premature infants, a trial of iNO may be considered in those at risk for PHT and/or
echocardiographic evidence of PHT beyond what is expected. Response to iNO in premature
infants has been shown to be improved in the presence of echocardiographic evidence of
aPHT(19). Sildenafil, a phosphodiesterase type 5 inhibitor, reduces PVR; it may be
considered in this population when iNO is not available, PHT is refractory to iNO (e.g. OI >
25), or with weaning from iNO(23, 55). The prostacyclin-cAMP pathway also has two
primary therapeutic options: Prostacyclin (PGI2) agonists and milrinone. PGI2 can be
administered via an intravenous, inhaled, or sub-cutaneous route and can provide both
systemic and pulmonary vasodilatation effects depending on the route and dose. Milrinone, a
selective phosphodiesterase 3 (PDE3) inhibitor, causes relaxation of vascular smooth muscle
and, in some settings, can enhance myocardial contractility (inotropy) and improve
myocardial relaxation (lusitropy). The endothelin toxin 1 pathway can be mediated by PO
administration of bosentan, a non-selective endothelin receptor antagonist.
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If echocardiography evaluation demonstrates RV dysfunction in infants with hemodynamic
compromise and PHT physiology, treatment strategies should be tailored to the pathogenic
contributions to altered RV performance; (1) decreased preload with volume optimization,
(2) increased PVR with RV afterload reduction, and/or (3) altered contractility with RV
inotropy enhancement(1). Prostaglandins (PgE1) to re-open or maintain the DA in aPHT
may also be considered in those neonates with PHT physiology but without a pathway to
offload the RV. The fulminant presentation of aPHT often necessitates a rapid and
multipronged approach. The cornerstone of its management is optimal lung parenchymal
support followed by early pulmonary vasodilator therapy, which in most cases will show
satisfactory response. On the other hand, because of the insidious nature and underlying
pathophysiology of cPHT, the primary treatment focus is on mitigating ongoing lung injury,
optimizing respiratory support, promoting growth and nutrition, and supporting RV function
(e.g. with preload reduction) rather than use of pulmonary vasodilators.(Table. 1)
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aPHT

acute pulmonary hypertension

CAMP

cyclic adenosine monophosphate

CDH

congenital diaphragmatic hernia

CGMP

cyclic guanyl monophosphate

CLD

chronic lung disease

cPHT

chronic pulmonary hypertension

DA

ductus arteriosus

EI

eccentricity index

FAC

fractional area change

HIE

hypoxic ischemic events

IDM

infants of diabetic mothers

iNO

inhaled nitric oxide

LV

left ventricle

mPAP

mean pulmonary artery pressure

MPI

myocardial performance index

PAAT

pulmonary artery acceleration time

PAP

pulmonary artery pressure

PASP

pulmonary artery systolic pressure

PADP

pulmonary artery diastolic pressure
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PCWP

pulmonary capillary wedge pressure

PBF

pulmonary blood flow

PDA

patent ductus arteriosus

PEP

pre-ejection period

PGI2

prostacyclin

PHT

pulmonary hypertension

PRV

pulmonary regurgitation velocity

RDS

respiratory distress syndrome

RV

right ventricle

RVET

right ventricle ejection time

RVO

right ventricular output

SVR

systemic vascular resistance

TR

tricuspid regurgitation

TRV

tricuspid valve regurgitation velocity

TAPSE

tricuspid annular plane systolic excursion
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Figure 1: Etio-Pathology Based Classification of Neonatal Pulmonary Hypertension
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AVM, arterial venous malformations; L-to-R, left to right; TAPVC, total anomalous
pulmonary vein connection; RDS, respiratory distress syndrome; CLD, chronic lung disease;
MAS, meconium aspiration syndrome; CDH, congenital diaphragmatic hernia; SSRI,
selective serotonin receptor inhibitor; NSAID, nonsteroidal anti-inflammatory drug; VSD,
ventricular septal defect; SPD, surfactant protein deficiency disorders; ABCA3, ATP
Binding Cassette Subfamily A Member 3; HIE, hypoxic ischemic encephalopathy; AS,
aortic stenosis; MS, mitral stenosis
Bold words indicate etiological entities of particular interest in prematurely born neonates
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Summary of comprehensive echocardiographic evaluation for neonatal pulmonary hypertension
Measurement

PHT Assessment

Indirect assessment of RVafterload
IVS configuration

Flattening at end-systole suggests >50% systemic RVSP Posterior systolic bowing into LV suggests
suprasystemic RVSP

Eccentricity Index

Elevated RV afterload if >1

PEP

Directly proportional to PAP

RVET

Inversely related to PA compliance

PAAT

Inverse correlation with mPAP (and PVR)

Estimation of Pulmonary Vascular Hemodynamics
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TRV max

Estimation of RVSP and PASP above RAP

PR

Estimation of mPAP and PADP

VSD/PDA

Estimation of RVSP and PASP from systemic pressure

RVVTI

Estimation of RV stroke volume

Dynamic compliance

Estimation of pulmonary vascular wall compliance

PA capacitance

Indirect measure of PVR

Right Ventricular Performance

Author Manuscript

FAC

Single planar interpretation of RV systolic ejection fraction

TAPSE

Longitudinal contractility of RV

RV size and RVH

Qualitative assessment of RV performance

MPI

Systolic and diastolic function

RVTDI

RV diastolic function

SD/DD

Impairment of RV diastolic function

STE Deformation Morphology

RV longitudinal strain and strain rate Areas, 4-chamber view of cavity and outflow tract dimensions

FAC, fractional area change; IVS, interventricular septum; PA, pulmonary artery; PADP, pulmonary artery diastolic pressure; PAP, pulmonary
artery pressure; PAAT, pulmonary artery acceleration time; PEP, pre-ejection period; PHT, pulmonary hypertension; PR, pulmonary regurgitation;
mPAP, mean pulmonary artery pressure; MPI, myocardial performance index; RAP, right atrial pressure; RVET, right ventricular ejection time; RV,
right ventricle; RVSP, right ventricular systolic pressure; SD/DD, systolic time to diastolic time ; STE, speckle-tracking echocardiography; TAPSE,
tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TR ,tricuspid regurgitation; VTI, velocity time integral.
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